- Open
- 6.00
- High
- 6.48
- Low
- 5.83
- Close
- 5.88
- Change
- -0.50 (-8.33%)
- Volume
- 160,896
| 22 Oct 2026 | 07:00:02 | Contract win |
| 15 Oct 2026 | 13:20:55 | Result of AGM |
| 15 Oct 2026 | 07:00:07 | AGM statement H1 trading and research update |
| 5 Oct 2026 | 07:00:07 | Launch of new customer-focused website |
| 29 Sep 2026 | Annual Report and Accounts (to 2026-03-31) | |
| 17 Sep 2024 | Annual Report and Accounts (to 2024-03-31) | |
| 10 Oct 2023 | Annual Report and Accounts (to 2023-03-31) |
Fusion Antibodies plc is a Contract Research Organisation (CRO) based in Northern Ireland that specializes in antibody discovery, engineering, and expression services for therapeutic and diagnostic applications. The company provides a comprehensive range of services, including the identification and optimization of antibodies, as well as the production of high-quality antibodies and cGMP-ready manufacturing cell lines. Fusion serves customers in the biopharmaceutical, veterinary, diagnostic, and life sciences sectors, focusing on both human and veterinary therapeutic markets. Its operations extend into various global markets, leveraging advanced technologies to enhance antibody performance and supply continuity.
| 22 Oct 2026 | 07:00:02 | Contract win |
| 15 Oct 2026 | 13:20:55 | Result of AGM |
| 15 Oct 2026 | 07:00:07 | AGM statement H1 trading and research update |
| 5 Oct 2026 | 07:00:07 | Launch of new customer-focused website |
| 29 Sep 2026 | Annual Report and Accounts (to 2026-03-31) | |
| 17 Sep 2024 | Annual Report and Accounts (to 2024-03-31) | |
| 10 Oct 2023 | Annual Report and Accounts (to 2023-03-31) |
Fusion Antibodies plc is a Contract Research Organisation (CRO) based in Northern Ireland that specializes in antibody discovery, engineering, and expression services for therapeutic and diagnostic applications. The company provides a comprehensive range of services, including the identification and optimization of antibodies, as well as the production of high-quality antibodies and cGMP-ready manufacturing cell lines. Fusion serves customers in the biopharmaceutical, veterinary, diagnostic, and life sciences sectors, focusing on both human and veterinary therapeutic markets. Its operations extend into various global markets, leveraging advanced technologies to enhance antibody performance and supply continuity.
| 22 Sept 2026 |
| 07:00:06 |
| Posting of Annual Report & Notice of AGM |
| 9 Oct 2026 |
| Week Ahead: Rio Tinto, Antofagasta, Bellway, Whitbread |
| 11 May 2026 | AIM movers: Nativo Resources exploration target and Fusion Antibodies patent grant |
| 11 Dec 2025 | AIM movers: Signs of recovery at RWS and ex-dividends |
| 17 Sept 2025 | AIM movers: Nexteq Brazilian order and Autins hit be production halt at JLR |
| 27 Aug 2025 | AIM movers: Fiinu readmitted and Victoria refinancing |
| 22 Sept 2026 |
| 07:00:06 |
| Posting of Annual Report & Notice of AGM |
| 9 Oct 2026 |
| Week Ahead: Rio Tinto, Antofagasta, Bellway, Whitbread |
| 11 May 2026 | AIM movers: Nativo Resources exploration target and Fusion Antibodies patent grant |
| 11 Dec 2025 | AIM movers: Signs of recovery at RWS and ex-dividends |
| 17 Sept 2025 | AIM movers: Nexteq Brazilian order and Autins hit be production halt at JLR |
| 27 Aug 2025 | AIM movers: Fiinu readmitted and Victoria refinancing |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £175m | +0.2% | |
| £100m | -0.1% | |
| £9m | -0.7% | |
FABFusion Antibodies plc | £7m | -0.6% |
| £6m | -0.3% | |
| £4m | -0.2% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £175m | +0.2% | |
| £100m | -0.1% | |
| £9m | -0.7% | |
FABFusion Antibodies plc | £7m | -0.6% |
| £6m | -0.3% | |
| £4m | -0.2% |
